How does the combination of ribociclib and letrozole perform in hormone receptor-negative breast cancer compared to standard treatments?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18760028
Cited by: 0

Abstract

Current evidence does not support the use of ribociclib and letrozole in hormone receptor-negative breast cancer, as studies primarily highlight benefits for hormone receptor-positive cases.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies PARP inhibition in cancer therapy

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
24 February 2026
Language
EN